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Background: Transglutaminase 2 (TG2) and its phosphorylation have been consistently found to be upregulated in
a number of cancer cell types. At the molecular level, TG2 has been associated with the activation of nuclear
factor-kappa B (NF-κB), protein kinase B (PKB/Akt) and in the downregulation of phosphatase and tensin
homologue deleted on chromosome 10 (PTEN). However, the underlying mechanism involved is not known. We
have reported that protein kinase A (PKA) induced phosphorylation of TG2 at serine-216 (Ser216) regulates TG2
function and facilitates protein-protein interaction. However, the role of TG2 phosphorylation in the modulation of
NF-κB, Akt and PTEN is not explored.
Methods: In this study we have investigated the effect of TG2 phosphorylation on NF-κB, Akt and PTEN using
embryonic fibroblasts derived from TG2 null mice (MEFtg2-/-) overexpressing native TG2 or mutant-TG2 (m-TG2)
lacking Ser216 phosphorylation site with and without dibutyryl cyclic-AMP (db-cAMP) stimulation. Functional
consequences on cell cycle and cell motility were determined by fluorescence activated cell sorting (FACS) analysis
and cell migration assay respectively.
Results: PKA activation in TG2 overexpressing MEFtg2-/- cells resulted in an increased activation of NF-κB and Akt
phosphorylation in comparison to empty vector transfected control cells as determined by the reporter-gene assay
and immunoblot analysis respectively. These effects were not observed in MEFtg2-/- cells overexpressing m-TG2.
Similarly, a significant downregulation of PTEN at both, the mRNA and protein levels were found in cells
overexpressing TG2 in comparison to empty vector control and m-TG2 transfected cells. Furthermore, Akt activation
correlated with the simultaneous activation of NF-κB and a decrease in PTEN suggesting that the facilitatory effect
of TG2 on Akt activation occurs in a PTEN-dependent manner. Similar results were found with MCF-7 and T-47D
breast cancer cells overexpressing TG2 and m-TG2 further supporting the role of TG2 phosphorylation in NF-κB
activation and in the downregulation of PTEN.
Conclusions: Collectively, these data suggest that phosphorylation of TG2 at Ser216 plays a role in TG2 mediated
activation of NF-κB, Akt and in the downregulation of PTEN. Blocking TG2 phosphorylation may provide a novel
strategy to attenuate NF-κB activation and downregulation of PTEN in TG2 overexpressing cancers.
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Transglutaminase 2 (TG2) is the most diverse and ubi-
quitous member of the TG family of enzymes that
catalyze posttranslational modification of proteins by
crosslinking proteins via E-(γ-glutamyl)lysine isopeptide
bonds or through incorporating primary amine at glu-
tamine residues [1,2]. In addition, TG2 can bind and
hydrolyze GTP and ATP, and functions as a G-protein in
cell signaling processes [3,4]. The GTP binding and
transamidation function of TG2 are inversely associated
with each other [5,6]. Furthermore, we have reported
that TG2 has intrinsic kinase activity and phosphorylates
a number of proteins involved in cell proliferation and/
or apoptosis [7-9]. Moreover, we have shown that TG2
undergoes phosphorylation in response to PKA activa-
tion and PKA induced phosphorylation of TG2 modu-
lates TG function and facilitates protein-protein
interaction [10].
TG2 has been found to be upregulated in a number of
cancers including breast, ovarian, pancreatic, colon can-
cers and shown to confer resistance to chemotherapeutic
drugs and promotes invasive potential of cancer cells
[2,11-15]. In contrast, downregulation of TG2 by small
interfering RNA or inhibition of TG2 activity by specific
inhibitors has been shown to increase their sensitivity to
chemo therapy-induced cell death and inhibition of cell
migration [16-18]. At the molecular level TG2 constitu-
tively activates prosurvival factors nuclear factor-kappa
B (NF-κB) and focal adhesion kinase/protein kinase B
(FAK/Akt) [19,20]. In addition, TG2 negatively regulates
the tumor suppressor phosphatase and tensin homologue
deleted on chromosome 10 (PTEN) [19]. However, the
underlying mechanism involved remains obscure. Al-
though a role for the crosslinking function of TG2 has
been implicated initially [20], however, no careful investi-
gations have been performed to make an unequivocal
conclusion. Furthermore, emerging evidence suggests that
transamidation function of TG2 is not involved in this
process [2].
Posttranslational modification of proteins by phosphor-
ylation plays a critical role in the regulation of protein
functions and in protein-protein interactions [21]. For
example, phosphorylation of NF-κB, PTEN and Akt is
known to play a critical role in the functional regulation
of these molecules [22-24]. Phosphoproteomic analysis
of cancer signaling networks have consistently identified
TG2 as a phosphoprotein in a number of cancer cell
types [25,26] http://www.phosphosite.org/proteinAction.
do?id=4135&showAllSites=true]. However, the kinase re-
sponsible for TG2 phosphorylation and functional conse-
quence of TG2 phosphorylation in cancer cell is not
known. We have reported that TG2 undergoes phos-
phorylation at serine-216 (Ser216) residue in response to
PKA activation [10]. In addition, we have shown thatphosphorylation of TG2 facilitates protein-protein inter-
action; upregulates TG2 kinase activity and inhibits
crosslinking activity [9,10]. Moreover, recently we have
found that overexpression of phospho mutant forms of
TG2 downregulates EGFR [11]. The cAMP-dependent
PKA signaling is known to interact with NF-κB signaling
and plays a crucial role in the pathogenesis of a number
of NF-κB-related diseases [27]. It is possible that phos-
phorylation of TG2 by PKA or other upstream kinases
play a role in TG2 mediated activation of NF-κB, Akt
and in the downregulation of PTEN which in turn con-
tribute to the invasive and chemoresistance potential of
TG2 in cancer. In this study, we have investigated the
functional impact of loss of TG2 phosphorylation at
Ser216 on TG2 mediated modulation of NF-κB, PTEN
and Akt in embryonic fibroblasts derived from TG2 null
mice (MEFtg2-/-) and in breast cancer cells. Herein we re-
port that phosphorylation of TG2 at Ser216 has an
important role in TG2 mediated activation of NF-κB
and in the downregulation of PTEN resulting into Akt
activation.
Results
PKA induced phosphorylation of TG2 at Ser216 facilitates
downregulation of PTEN in MEFtg2-/- cells
PKA that plays an important role in the pathogenesis of
a number of NF-κB related diseases also phosphorylates
TG2 at Ser216 residue [9,10,27]. PKA induced phosphor-
ylation of TG2 at Ser216 was further confirmed using
MEFtg-/- cells overexpressing Myc tagged wild-type TG2
and Ser216Ala-TG2 mutant (m-TG2) lacking Ser216
phosphorylation site (Figure 1A). Since TG2 activates
NF-κB, we explored whether PKA induced phosphoryl-
ation of TG2 at Ser216 play a role in TG2 mediated acti-
vation of NF-κB and subsequent downregulation of
PTEN. To determine this, MEFtg2-/- cells were trans-
fected with Myc tagged wild-type TG2 and Ser216Ala-
TG2 mutant (m-TG2). Expression level of wild-type
TG2 and m-TG2 was confirmed by immunoblotting
using anti-Myc antibody (Figure 1B). 48 h post-
transfection, cells were incubated with db-cAMP in the
presence and absence of a PKA specific inhibitor H89
and processed for further analysis [9,10]. Western
immunoblot analysis revealed that overexpression of
TG2 was sufficient to significantly downregulate PTEN
(may be due to adequate basal PKA activity in these
cells) in comparison to empty vector transfected control
group (Figure 1B-C). Furthermore, db-cAMP stimula-
tion led to further decrease in PTEN protein level that
was partially protected in the presence H89 (Figure 1
B-C). On the contrary, m-TG2 fails to decrease PTEN
protein levels even after db-cAMP induced PKA activa-
tion suggesting involvement of Ser216 in the downregula-
tion of PTEN (Figure 1B-C). A similar change in the
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Figure 1 PKA induced phosphorylation of TG2 at Ser216 facilitates downregulation of PTEN in MEFtg2-/- cells. (A) Immunoblot showing
Ser216 in TG2 as a predominant phosphorylation site in response to PKA activation by cAMP. MEFtg2-/- cells were transfected with Myc tagged
wild type TG2 and mutant-TG2 (lacking Ser216 phosphorylation site) constructs. 48 h post-transfection, cells were serum starved and incubated
with or without db-cAMP (100 μM) in the presence or absence of a PKA inhibitor H89 (100 nM). Cells were harvested and cell lysates were
analyzed by western immunoblotting using anti-phospho-serine and anti-Myc antibodies. Representative immunoblots of three different
experiments are shown. (B) MEFtg2-/- cells were transfected with various TG2 constructs. 48 h post-transfection, cells were serum starved and
incubated with or without db-cAMP (100 μM) in the presence or absence of a PKA inhibitor H89 (100 nM). Cells were harvested and cell lysates
were analyzed by western immunoblotting using protein and phospho-specific antibodies. Anti-Myc immunoblot showing expression levels of
wild-type TG2 and m-TG2 is shown as a control. Representative immunoblots of four different experiments are shown. (C) Histograms showing
relative quantification of protein/phospho-proteins as shown in left panel. (D) Histogram showing pNF-κB-MetLuc2-reporter gene activity in
MEFtg-/- cells transfected with TG2 and m-TG2 constructs. Data are represented as mean± SEM, n = 4. * P< 0.05 and ** P< 0.01 (TG2 vs. empty
vector control); # P< 0.05 (m-TG2 vs. TG2).
Wang et al. BMC Cancer 2012, 12:277 Page 3 of 12
http://www.biomedcentral.com/1471-2407/12/277
Wang et al. BMC Cancer 2012, 12:277 Page 4 of 12
http://www.biomedcentral.com/1471-2407/12/277phosphorylation of PTEN was found using p-PTEN spe-
cific monoclonal antibody (Figure 1B-C). This antibody
detects endogenous levels of PTEN only when phos-
phorylated at Ser380, Thr382 and Thr383. These phosphor-
ylation sites are present at the carboxy-terminal
noncatalytic regulatory domain, which regulates its sta-
bility and play an important role in the regulation of its
biological activity [28,29]. Interestingly, an apparent dif-
ference in PTEN and pPTEN levels was found in cells
expressing m-TG2 with and without db-cAMP treat-
ment. This would indicate that in addition to Ser216,
additional serine residue(s) in TG2 is also involved in
this process and is consistent with the phosphorylation
level of TG2 and m-TG2 observed in response to db-
cAMP in MEFtg2-/- cells (Figure 1A).
The NF-κB/Rel transcription factors are present in
the cytosol in an inactive state associated with the in-
hibitory IκB proteins (20). Activation occurs via phos-
phorylation of IκB followed by proteasome-mediated
degradation that results in the release and nuclear
translocation of active NF-κB (20,22). As a prelude to
NF-κB activation, we examined IκBα protein levels in
cells overexpressing TG2 and m-TG2. IκBα was found
to be significantly downregulated in TG2 overexpres-
sing cells in comparison to empty vector transfected
and m-TG2 overexpressing cells with db-cAMP stimu-
lation (Figure 1B-C). No significant difference was
found between m-TG2 overexpressing cells and empty
vector transfected control group (Figure 1 B-C). To
confirm that TG2 induced downregulation of PTEN is
a consequence of NF-κB activation, we performed luci-
ferase reporter-gene assay using a pNF-κB-MetLuc2-re-
porter. A significant upregulation of luciferase activity
was observed in cells transfected with TG2 in compari-
son with empty vector transfected cells (Figure 1D).
However, an increase in luciferase activity was not
observed in m-TG2 transfected cells (Figure 1D). Most
importantly, the luciferase activity inversely correlated
with PTEN levels suggesting involvement of NF-κB in
this process (Figure 1D). Collectively, these data suggest
that phosphorylation of TG2 at Ser216 facilitates TG2
mediated activation of NF-κB and downregulation of
PTEN.
Phosphorylation of TG2 at Ser216 facilitates
downregulation of PTEN in breast cancer cells
To verify that TG2 induced activation of NF-κB and the
downregulation of PTEN as observed in TG2 overex-
pressing MEFtg2-/- is not cell specific and pertinent to
TG2 protein, experiments were repeated using MCF-7
and T-47D breast cancer cells. A similar downregulation
of PTEN protein level in MCF-7 and T-47D cells were
found as in the case of MEFtg2-/- cells overexpressing
TG2 (Figure 2A-B). However, a differential effect onphospho-PTEN was observed in MCF-7 and T-47D in
response to db-cAMP stimulation (Figure 2A-B). These
differences may be attributed to differences in the
prevailing signaling pathways in MCF-7 and T-47D cells
that are known to target TG2. For example, TG2 has
been identified as a target protein in EGFR signaling and
EGFR expression level significantly differ in these two
cell types [30,31]. Furthermore, similar to MEFtg2-/- cells,
pNF-κB-MetLuc2-reporter gene activity was upregulated
in both cell lines overexpressing TG2 (Figure 2C). Taken
together these data further confirms a role of TG2 phos-
phorylation in the activation of NF-κB and in the down-
regulation of PTEN.
TG2 attenuates transcription of PTEN mRNA
To determine whether TG2 mediated down regulation
of PTEN occurs at the protein level or is a consequence
of attenuated transcription, PTEN mRNA expression
level was analyzed by real-time PCR in MEFtg2-/-, MCF-7
and T47D cells overexpressing TG2 and m-TG2. A sig-
nificant decrease in PTEN mRNA expression was found
only in cells overexpressing TG2 but not in m-TG2
overexpressing cells in comparison with empty vector
transfected control group suggesting that TG2 mediated
downregulation of PTEN occurs at the transcription
level (Figure 3).
TG2 mediated activation of NF-κB and Akt are
interconnected
TG2 has been implicated in the activation of Akt and
PTEN is a major negative regulator of the phosphatidyli-
nositol 3 kinase (PI3K)/Akt signaling pathway [19,32].
The main substrates of PTEN are inositol phospholipids
generated by the activation of PI3K [33]. To investigate
whether TG2 mediated activation of NF-κB and Akt are
interconnected, we determined the phosphorylation sta-
tus of Akt-Ser473, which is an important downstream
substrate of PI3K and known to be upregulated in a
number of cancers. In all three cell lines examined that
is MEFtg2-/-, MCF-7 and T-47D, Akt phosphorylation
was found to be increased in cells overexpressing TG2
in comparison with empty vector transfected control
group (Figure 4). No difference in Akt phosphorylation
was observed in cells overexpression m-TG2 in compari-
son with empty vector control group. However, a differ-
ence was apparent in Akt phosphorylation between cells
overexpressing TG2 and m-TG2 which was significantly
higher in TG2 overexpressing MEFtg2-/- and MCF-7 cells
with db-cAMP treatment (Figure 4). Unlike MEFtg2-/-
and MCF-7, an increase in Akt phosphorylation was
observed in m-TG2 overexpressing T-47D cells in com-
parison with empty vector transfected control cells with
db-cAMP stimulation. Most importantly, Akt activation
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Figure 2 PKA induced phosphorylation of TG2 at Ser216 facilitates downregulation of PTEN in breast cancer cells. (A) MEF-7 and (B)
T-47D breast cancer cells were transfected with various TG2 constructs. 48 h post-transfection, cells were serum starved and incubated with or
without db-cAMP (100 μM) in the presence or absence of a PKA inhibitor H89 (100 nM). Cells were harvested and cell lysates were analyzed by
western immunoblotting using protein and phospho-specific antibodies. Representative immunoblots of three different experiments are shown.
Histograms showing relative quantification of protein/phospho-proteins are shown in right panel. (C) Histograms showing pNF-κB-MetLuc2
-reporter gene activity in MCF-7 and T-47D cells transfected with TG2 and m-TG2 constructs. Data are represented as mean± SEM, n = 3.
* P< 0.05 (TG2 vs. vector control); ** P <0.01 (TG2 vs. vector control); # P< 0.05 (m-TG2 vs. TG2). WT, wild-type TG2; S216A,
Ser216Ala-TG2 mutant.
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http://www.biomedcentral.com/1471-2407/12/277inversely correlated with the downregulation of PTEN.
Taken together, these data suggest that phospho-TG2
mediated activation of NF-κB and Akt are intercon-
nected with each other and involves downregulation of
PTEN.Overexpression of TG2 in MEFtg2-/- enhances
cell migration
To determine the functional consequence of the loss of
phosphorylation at Ser216 in TG2, we studied the effect
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Figure 3 PKA induced phosphorylation of TG2 at Ser216
facilitates downregulation of PTEN mRNA. Histogram showing
relative quantification (RQ) of PTEN mRNA expression levels as
determined by real-time PCR in response to PKA activation by
db-cAMP in MEFtg2-/- and breast cancer cells in comparison to
empty vector control group. The levels of mRNA were normalized
against GAPDH mRNA. Cell transfection and treatments were
performed as described in the figure legends 1 and 2. Data are
represented as mean± SEM, n = 4. **P< 0.01 (TG2 vs. vector control).
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alone led to significant increase in the migration of
MEFtg2-/- cells in comparison to empty vector trans-
fected control cells which was further enhanced after
db-cAMP stimulation (Figure 5). Furthermore, db-
cAMP effect was significantly reduced in the presence of
PKA inhibitor H89 suggesting a role of PKA in this
process. On the contrary, m-TG2 overexpressing cells
had no significant effect on cell migration in comparison
with empty vector transfected control group even after
db-cAMP treatment (Figure 5). However, a difference in
cell migration was apparent between TG2 and m-TG2 in
response to db-cAMP stimulation which was signifi-
cantly lower in m-TG2 expressing cells suggesting a role
of TG2 phosphorylation in TG2 mediated cell migration.
Similarly, TG2 effect on cell migration was also inhibited
by Akt inhibitor MK-2206 suggesting a role of Akt in
TG2-induced cell migration (Figure 5).
Cell cycle progression in MEFtg2-/- and breast cancer cells
Akt and NF-κB activation is known to facilitate cell sur-
vival and cell proliferation in a number of cancers [34].
Since TG2 modulates phosphorylation of Akt at residues
known to be involved in Akt activation, we evaluated the
progression of MEFtg2-/- and MCF-7 breast cancer cells
overexpressing TG2 and m-TG2 through the cell cycle
phases by FACS analysis. An increased progression of
MEFtg2-/- and MCF-7 cells through the S phase was
found in TG2 overexpressing cells (Figure 6). In
MEFtg2-/- cells, an increase of ~27% was observed
whereas in MCF-7 cells an increase of ~54% was found
in comparison to empty vector transfected control group
(Figure 6). However, a difference in the range of 30-38%
was observed in m-TG2 overexpressing MEFtg2-/- and
MCF-7 cells through S phase in comparison with TG2
transfected cells, which was lower in m-TG2 overexpres-
sing cells (Figure 6). Taken together, these data suggest
that the loss of TG2 phosphorylation at Ser216 residue
leads to significant reduction in cell progression through
S phase.
Discussion
PKA signaling plays an important role in the pathogen-
esis of a number of NF-κB related diseases including
Akt
pAkt
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Figure 4 TG2 mediated activation of NF-κB and Akt are interconnected. Left panel: Representative immunoblots showing phosphorylation
levels of Akt in MEFtg2-/- and breast cancer cells overexpression TG2 and m-TG2 under the same experimental conditions as shown in Figure 1.
Akt immunoblots are shown as controls. Right panel: Histograms showing quantitative difference in Akt phosphorylation as shown in the
left panel. Data are represented as mean± SEM, n = 4. * P< 0.05 (TG2 vs. vector control); # P< 0.05 (m-TG2 vs. TG2); @ P< 0.05
(m-TG2 vs. vector control).
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zumab in human breast cancer cells [27,35]. In patient
samples, PKA signaling appeared to be enhanced in
residual disease remaining after trastuzumab-containing
neoadjuvant therapy [35]. Furthermore, in breast can-
cer cells the PKA signaling synergizes with NF-κB sig-
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Figure 5 Overexpression of TG2 in MEFtg2-/- enhances cell
migration. The ability of TG2 and m-TG2 to induce cell migration
was tested in response to db-cAMP (100 μM) stimulation in the
presence of PKA inhibitor H89 (100 nM) and Akt inhibitor MK-2206
(20 nM). The data represent the mean± SEM for n = 9; * P< 0.05
(TG2 vs. vector control); # P< 0.05 (m-TG2 vs. TG2); @ P< 0.05 (TG2
vs. Akt inhibitor).dependent transcriptional activity whereas PKA inhibi-
tors suppress NF-κB-induced cell proliferation and
multiple NF-κB-dependent anti-apoptotic gene expres-
sion [27,35]. However, various signaling intermediates
and protein substrates that mediate such effects remain
to be identified. Previously, we have shown that PKA
induced phosphorylation of TG2 at Ser216 regulates
TG2 function and facilitates its interaction with
phospho-serine/threonine binding protein 14-3-3 [10].
In this study, using MEFtg2-/- cells overexpressing TG2
or m-TG2 (lacking Ser216 phosphorylation site), we un-
raveled a novel role of TG2 phosphorylation at Ser216
in the activation of NF-κB, Akt and in the downregu-
lation of PTEN. We provide evidence that phosphoryl-
ation of TG2 at Ser216 facilitates TG2 mediated NF-κB
activation, which induces downregulation of PTEN,
resulting in Akt activation. As TG2 induced activation
of Akt was found in the absence of receptor tyrosine
kinase or PI3K stimulation, this would imply that TG2
induced activation of Akt under the experimental con-
dition used in this study mainly occurs through down-
regulation of PTEN. Most importantly, the loss of
phosphorylation at Ser216 in TG2 completely blocked
TG2-induced effect on NF-κB activation and downre-
gulation of PTEN mRNA as determined by reporter-







G1 G2 S G1 G2 S
Vector 61.20±5.73 10.78±1.32 28.01±2.67 48.38±4.58 33.33±2.92 18.30±2.01
TG2 55.95±5.37 8.60±0.96 35.46±3.74 49.32±5.21 22.47±2.50 28.21±2.89
mTG2 59.89±6.03 15.15±1.49 24.96±2.41 57.44±5.63 19.82±2.02 22.75±1.98
Figure 6 Cell cycle progression in MEFtg2-/- and MCF-7 breast cancer cells overexpressing TG2 and m-TG2. Cell cycle distribution is shown
in MEFtg2-/- (left panel) and MCF-7 breast cancer cells (right panel). Cells at 60% confluency show an enhanced relative distribution in the S phase
in TG2 overexpressing cells and a reduced relative distribution in the S phase in m-TG2 overexpressing cells (upper panels and table at bottom).
The experiment was repeated three times. The table shows the mean± SEM as a percentage for three independent experiments.
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sphorylates PIP3 that is produced by PI3K and function
as a ubiquitous inhibitor of PI3K-dependent signaling
[33,34]. The PI3K/PTEN signaling controls a large and
diverse set of PIP3-binding proteins, the best character-
ized of which are the Akt protein kinases [34]. In this
way, PI3K and PTEN orchestrate cell responses to
growth factors, cytokines, integrins and other intercellu-
lar mediators and contribute to the growth, motility, sur-
vival and metabolic responses of many cell types [34].
Our data indicates that phosphorylation of TG2 may fa-
cilitate integration of factors into NF-κB signaling cas-
cade and contribute to the growth, survival and motilityof cancer cells as reported earlier [1,2]. In this context it
should be noted that the TG2 promoter contains func-
tional NF-κB binding elements [36,37]. It is plausible
that TG2 mediated activation of NF-κB might payback
by upregulation of TG2, and create a feed-forward loop
involving phospho-TG2-NF-κB-TG2 leading to sustained
inhibition of PTEN and constitutive activation of Akt in
cancers characterized by TG2 upregulation along with
constitutive activation of NF-κB.
The motif containing Ser216 phosphorylation site par-
tially overlaps with a functional BH3-only motif identi-
fied in TG2 [38]. The BH3 motif identified in TG2
facilitates interaction of TG2 with the pro-apoptotic Bcl-
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bers Bcl-2 and Bcl-XL [38]. In this context it should be
noted that the phosphorylation of a specific serine resi-
due in BH3 domain of BAD mediates its interaction with
Bcl-XL and increases the accessibility of another serine
residue within BH3 domain to PKA induced phosphoryl-
ation [39]. The motif containing Ser216 in TG2 contains
additional serine residue (i.e., Ser212) which is also
present as a PKA consensus phosphorylation site
(209RDCSRRSSPVYVGRV223). It is possible that phos-
phorylation of TG2 at Ser216 plays a similar role in its
interaction with Bcl-2 family members which in turn
may attenuate interaction of TG2 with pro-apoptotic
members or facilitate interaction with anti-apoptotic
members of Bcl-2 family of proteins. Furthermore, we
have reported that phosphorylation of TG2 at Ser216
facilitates its interaction with protein 14-3-3, a phospho-
serine/threonine binding protein [10]. Moreover, 14-3-3
protein is known to target BH3-only protein and emer-
ging evidence suggests that 14-3-3 proteins are involved
in cancer development [40]. It is conceivable that cancer
promoting function of TG2 may also be mediated
through phosphorylation-dependent interaction with 14-
3-3 and Bcl-2 family of proteins that warrants further
investigation.
As TG2 has been identified as a phospho-protein in
multiple cancer cells/tissues, this would imply that TG2
may serve as a target protein for a number of upstream
kinases and mediate the effect of tumor promoting fac-
tors. For instance, although we have identified Ser216 as
a PKA phosphorylation site, the phosphorylation of
Ser216 by other kinases may not be ruled out. This may
also explain the differences observed in Akt phosphoryl-
ation and pPTEN/PTEN levels in three different cell
lines used in this study. For example, TG2 has been
identified as a downstream target of EGFR, and EGFR
expression level is known to significantly vary in various
breast cancer cell lines including MCF-7 and T-47D cells
[41]. Moreover, recently we have reported that TG2
attenuates ligand-dependent downregulation of EGFR in
EGFR expressing cells and overexpression of phospho
mutant forms of TG2 downregulates EGFR [11]. Ana-
lysis of TG2 motif spanning Ser216 with phospho-motif
servers (http://networkin.info/version_2_0/search.php
and http://www.hprd.org) predicted Ser212 and Ser216 as
potential sites of phosphorylation by a number of
kinases known to be involved in tumorigenic signals
such as calmodulin-dependent protein kinase II, casein
kinase II, MAPK, PKC, RSK and cdk5. In addition to
Ser216, phosphorylation of TG2 at Tyr219 and Tyr369 has
been identified in a number of cancer cells [25,26]. It is
possible that phosphorylation of TG2 facilitates integra-
tion of multiple signaling pathways to NF-κB and PI3K/
Akt signaling and facilitate tumorogenesis. Furthermore,this would imply that depending on upstream stimuli
TG2 may contribute to Akt activation in a PTEN-
dependent and -independent manner (Figure 7).
Conclusions
In summary, data presented here provides new insight
into the underlying mechanism involved in TG2
mediated activation of NF-κB, Akt and in the downregu-
lation of PTEN that have been implicated in the invasive
and chemoresistant potential of cancers. Further studies
to identify the factors that are involved in the regulation
of TG2 phosphorylation at Ser216 and other potentially
important phosphorylation sites will hopefully provide
information for the development of novel strategies to
reduce the enhanced cancer growth associated with TG2
upregulation. Continued research will determine if inter-
fering with the phosphorylation of TG2 has preventive
or therapeutic application in cancer.
Methods
Reagents
MEFtg2-/- cells were obtained from TG2 null mice [9,10].
MCF-7 and T47D breast cancer cells were obtained
from American Type Culture Collection (Danvers, MA)
and cell culture reagents and fetal bovine serum from
Invitrogen (Carlsbad, CA). Akt (#9916) and PTEN
(#9652) sampler kit and anti-Myc (#2272) antibodies
were purchased from Cell Signaling Technology (Dan-
vers, MA) and HRP-conjugated secondary antibodies
were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA) and enhanced chemiluminescence (ECL)
reagents from Promega (Madison, WI). Other reagents
were purchased from Sigma-Aldrich (Oakville, ON) or
as otherwise stated.
Animals
TG2 knockout C57BL/6 mice were generously provided
by Dr. Nikolaos Frangogiannis (Baylor College of Medi-
cine, Houston, Texas, USA) with permission from Dr.
Gerry Melino (University of Leicester, UK). Experiments
involving mice were performed as approved by the Ani-
mal Care Committee of the University of Manitoba.
Cell culture and transfection
MEF and breast cancer cell culture and treatments were
performed as described before [9,10]. The pCMV vector
containing Myc tagged human TG2 (Myc-TG2, Origene
Technology, USA) was used to generate TG2 mutant.
Ser216Ala-TG2 mutant lacking Ser216 phosphorylation
sites was made by a site-directed mutagenesis kit
using two complementary nucleotide primers (forward,
5' CTCCCGCCGCAGCGCCCCCGTCTACGTG 3' and
reverse, 5' CACGTAGACGGGGGCGCTGCGGCGGG
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Figure 7 Schematic diagram showing potential mechanism involved in tumor promoting function of TG2. We propose that depending
on upstream stimuli TG2 contribute to Akt activation in a PTEN-dependent and -independent manner.
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by DNA sequencing. Transfections with various con-
structs were performed using FuGENE HD transfection
reagent (Roche, Germany) according to the manufac-
turer’s instructions. Cells treatments were performed
48 h post-transfection. Cell culture medium was
exchanged for serum free media, and cells were serum
starved for 6 h. Subsequently cells were treated with
db-cAMP (100 μM) for 1 h or as otherwise stated in the
presence and absence of PKA inhibitor H89 (100 nM).Western blotting
Cell lysates were prepared using lysis buffer (Sigma-
Aldrich), containing protease inhibitor cocktail as
described previously [9]. Protein concentrations of
lysates were determined by the Bradford protein assay
with bovine serum albumin (BSA) as the standard. Pro-
teins were resolved on 10% SDS-PAGE and transferred
onto nitrocellulose membranes. Membranes were
blocked in 5% blocking grade milk and processed for in-
cubation with primary and HRP-conjugated secondary
antibodies [9,10]. Protein band was visualized using ECL
and Kodak film.Real-time PCR
Total RNA was extracted using RNA easy plus mini kit
(Qiagen, Canada) from MEFtg-/- and breast cancer cellstransfected with empty vector, wild type TG2 and mutant-
TG2 (m-TG2, lacking Ser216 phosphorylation site) con-
structs. The cDNA was synthesized from total RNA (1 μg)
using reverse transcriptase and oligo-deoxythymidine pri-
mers [42]. The following primers were used for amplification
of cDNA using real-time PCR: PTEN, forward 5’-AAGAC-
CATAACCCACCACAGC-3’ and reverse 5’-TCATTACAC-
CAGTTCGTCCCT-3’; GAPDH, forward 5’-CATCACCA
TCTTCCAGGAGCG-3’ and reverse 5’-TGACCTTGCC
CACAGCCTTG-3’. Amplification conditions used were 40
cycles of denaturation for 30 s at 94°C, 30 s annealing at
50°C, and 30 s extension at 72°C.
FACS analysis
Cell cycle analysis was performed by fluorescence acti-
vated cell sorting (FACS) as described before [9]. In
brief, MEFtg-/- cells were transfected with various TG2
plasmids for 48 hours. Subsequently cells were collected
by trypsinization, pelleted at 800 x g for 10 min, and
fixed in 70% ethanol. DNA content was evaluated by
flow cytometry with propidium iodide (PI) staining.
Cell motility assay
MEFtg2-/- cells were used for the cell motility assays.
Polycarbonate filters (Thermo scientific, 8 um pore size)
with cells which were transfected with various TG2 con-
structs were placed in wells of 6-well plates. Incubation
was carried out with and without db-cAMP (100 μM) in
the presence and absence of PKA inhibitor H89 (100
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http://www.biomedcentral.com/1471-2407/12/277nM). The filters were removed and fixed in 1:10 diluted
formalin for 1 h at RT. Cells on upper filter surface were
removed carefully with cotton swab. The filters were
stained in hematoxylin for 10 min, and cells on the
lower surface of the filter were counted under a light
microscope [43].
Ready-To-Glow secreted luciferase reporter assay
MEFtg2-/- and breast cancer cells were co-transfected
with TG2 and pNFkB-MetLuc2-Reporter (Clontech,
Mountain View, CA) constructs as per manufacturer’s
protocol. Subsequently, cells were serum-starved for 6
hours, treated with 100 μM db cAMP for 1.5 h. Samples
of supernatant media (100 μL) were collected. Subse-
quently 10 μL of 1 x substrate/reaction buffer was added
to each sample and activity was measured using a
Luminometer (Lumat LB 9507). The transfection effi-
ciency was normalized by adding substrate buffer to cell
lysates of each sample and light signals were recorded
using a Luminometer [42].
Statistical analysis
Experimental results are shown as means ± SEM. One-
way ANOVA with Dunnett’s test was used for multiple
comparisons. P values <0.05 were considered significant
difference.
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